Roche’s Phase IIa study of R1626, an investigational therapy for chronic hepatitis C virus (HCV) infection, has shown a significant end-of-treatment response rate when given in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). R1626 also shows a high barrier to the development of resistance.     After four weeks of treatment with this triple combination, followed by 44 weeks of Pegasys and Copegus, levels of HCV were undetectable in 84% of patients infected with ...